MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$9,181K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Non-refundable sublicense and tr...
    • Share-based compensation
    • Prepaid research and development
    • Others
Negative Cash Flow Breakdown
    • Right of use assets and operatin...
    • Net gain on lease terminations
    • Accounts payable
    • Accrued expenses and other curre...
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-7,780
-7,600
-12,983
-32,539
Depreciation and amortization
25
129
177
181
Share-based compensation
525
556
609
611
Amortization of premium and discount on marketable securities, net
-
-
0
0
Impairment of long-lived assets
-
-
3,508
2,637
Other non-cash items
-
-
0
0
Net gain on lease termination
-
633
-
-
Net gain on lease terminations
1,977
600
-
-
Prepaid expenses and other current assets, and other assets
-158
53
-1,034
235
Prepaid research and development
-471
-107
-490
33
Non-refundable sublicense and transition services payments received
2,500
-
0
2,500
Right of use assets and operating lease liabilities
2,359
4,973
127
122
Accounts payable
-408
197
161
66
Accrued expenses and other current liabilities
-328
-758
652
-72
Net cash provided by (used in) operating activities
-9,181
-12,987
-6,479
-4,853
Sales or maturities of marketable securities
-
-
0
0
Sale of property and equipment and other assets
-
-
-
0
Sales of property and equipment and other assets
0
20
1,170
-
Net cash provided by (used in) investing activities
0
20
0
0
Proceeds from the issuance of common stock under employee stock purchase plan
-
-
9
0
Net cash provided by (used in) financing activities
-
-
9
0
Net increase (decrease) in cash and cash equivalents
-
-12,967
-
-
Net increase (decrease) in cash and cash equivalents
-9,181
-12,967
-6,470
-4,853
Cash and cash equivalents at beginning of period
33,336
46,303
52,773
37,573
Cash and cash equivalents at end of period
24,155
33,336
46,303
52,773
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net increase(decrease) in cash and cash...-$9,181K (-145.78%↓ Y/Y)Non-refundable sublicense andtransition services...$2,500K (65.02%↑ Y/Y)Share-based compensation$525K (-70.52%↓ Y/Y)Prepaid research anddevelopment-$471K (-813.64%↓ Y/Y)Prepaid expenses andother current assets,...-$158K (-127.67%↓ Y/Y)Depreciation andamortization$25K (-93.24%↓ Y/Y)Net cash provided by(used in) operating...-$9,181K (54.50%↑ Y/Y)Canceled cashflow$3,679K Net loss-$7,780K Right of use assets andoperating lease...$2,359K (997.21%↑ Y/Y)Net gain on leaseterminations$1,977K Accounts payable-$408K (-124.68%↓ Y/Y)Accrued expenses andother current...-$328K (87.55%↑ Y/Y)

Passage BIO, Inc. (PASG)

Passage BIO, Inc. (PASG)